BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20574843)

  • 1. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
    Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
    Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants in DNA repair genes and the risk of cutaneous malignant melanoma in melanoma-prone families with/without CDKN2A mutations.
    Liang XS; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM; Yang XR
    Int J Cancer; 2012 May; 130(9):2062-6. PubMed ID: 21671477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
    Yang XR; Pfeiffer RM; Wheeler W; Yeager M; Chanock S; Tucker MA; Goldstein AM
    Int J Cancer; 2009 Dec; 125(12):2912-7. PubMed ID: 19626699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
    Burke LS; Hyland PL; Pfeiffer RM; Prescott J; Wheeler W; Mirabello L; Savage SA; Burdette L; Yeager M; Chanock S; De Vivo I; Tucker MA; Goldstein AM; Yang XR
    PLoS One; 2013; 8(8):e71121. PubMed ID: 23990928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi.
    Falchi M; Bataille V; Hayward NK; Duffy DL; Bishop JA; Pastinen T; Cervino A; Zhao ZZ; Deloukas P; Soranzo N; Elder DE; Barrett JH; Martin NG; Bishop DT; Montgomery GW; Spector TD
    Nat Genet; 2009 Aug; 41(8):915-9. PubMed ID: 19578365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families.
    Liang X; Pfeiffer RM; Li WQ; Brossard M; Burke LS; Wheeler W; Calista D; Fargnoli MC; Ghiorzo P; Peris K; Bianchi-Scarra G; Chaudru V; Zelenika D; Maeder D; Burdette L; Yeager M; Chanock S; Landi MT; Demenais F; Tucker MA; Goldstein AM; Yang XR
    J Invest Dermatol; 2014 Feb; 134(2):481-487. PubMed ID: 23892592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.
    Chaudru V; Chompret A; Bressac-de Paillerets B; Spatz A; Avril MF; Demenais F
    J Natl Cancer Inst; 2004 May; 96(10):785-95. PubMed ID: 15150307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
    Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
    J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
    Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
    J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetics of hereditary melanoma and nevi. 1998 update.
    Greene MH
    Cancer; 1999 Dec; 86(11 Suppl):2464-77. PubMed ID: 10630172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common genetic variants in the 9p21 region and their associations with multiple tumours.
    Gu F; Pfeiffer RM; Bhattacharjee S; Han SS; Taylor PR; Berndt S; Yang H; Sigurdson AJ; Toro J; Mirabello L; Greene MH; Freedman ND; Abnet CC; Dawsey SM; Hu N; Qiao YL; Ding T; Brenner AV; Garcia-Closas M; Hayes R; Brinton LA; Lissowska J; Wentzensen N; Kratz C; Moore LE; Ziegler RG; Chow WH; Savage SA; Burdette L; Yeager M; Chanock SJ; Chatterjee N; Tucker MA; Goldstein AM; Yang XR
    Br J Cancer; 2013 Apr; 108(6):1378-86. PubMed ID: 23361049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
    Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
    J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variants at the 9p21 locus and melanoma risk.
    Maccioni L; Rachakonda PS; Bermejo JL; Planelles D; Requena C; Hemminki K; Nagore E; Kumar R
    BMC Cancer; 2013 Jul; 13():325. PubMed ID: 23816148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
    Lesueur F; de Lichy M; Barrois M; Durand G; Bombled J; Avril MF; Chompret A; Boitier F; Lenoir GM; ; Bressac-de Paillerets B; Baccard M; Bachollet B; Berthet P; Bonadona V; Bonnetblanc JM; Caron O; Chevrant-Breton J; Cuny JF; Dalle S; Delaunay M; Demange L; De Quatrebarbes J; Doré JF; Frénay M; Fricker JP; Gauthier-Villars M; Gesta P; Giraud S; Gorry P; Grange F; Green A; Huiart L; Janin N; Joly P; Kérob D; Lasset C; Leroux D; Limacher JM; Longy M; Mansard S; Marrou K; Martin-Denavit T; Mateus C; Maubec E; Olivier-Faivre L; Orlandini V; Pujol P; Sassolas B; Stoppa-Lyonnet D; Thomas L; Vabres P; Venat L; Wierzbicka E; Zattara H
    Br J Cancer; 2008 Jul; 99(2):364-70. PubMed ID: 18612309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
    Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
    JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree.
    Florell SR; Meyer LJ; Boucher KM; Grossman D; Cannon-Albright LA; Harris RM; Samlowski WE; Zone JJ; Leachman SA
    J Invest Dermatol; 2008 Aug; 128(8):2122-5. PubMed ID: 18337833
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetics of cutaneous melanoma and nevi.
    Greene MH
    Mayo Clin Proc; 1997 May; 72(5):467-74. PubMed ID: 9146691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood DNA methylation, nevi number, and the risk of melanoma.
    Pergoli L; Favero C; Pfeiffer RM; Tarantini L; Calista D; Cavalleri T; Angelici L; Consonni D; Bertazzi PA; Pesatori AC; Landi MT; Bollati V
    Melanoma Res; 2014 Oct; 24(5):480-7. PubMed ID: 25026000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A variants in a population-based sample of Queensland families with melanoma.
    Aitken J; Welch J; Duffy D; Milligan A; Green A; Martin N; Hayward N
    J Natl Cancer Inst; 1999 Mar; 91(5):446-52. PubMed ID: 10070944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.